CTOs on the Move

Medac Corporation

www.medac.com

 
Medac Corporation is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.medac.com
  • 804 Scott Nixon Memorial Dr
    Augusta, GA USA 30907
  • Phone: 706.650.0705

Executives

Name Title Contact Details
Sam Bruce
Chief Information Security Officer Profile

Similar Companies

R.D. Laboratories

R.D. Laboratories is a Washington, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AandA Phamachem

A&A Phamachem Inc. is a Nepean, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Concerto HealthAI

Concerto HealthAI is a global leader in real-world data, AI technology, and real-world evidence services for precision oncology and dedicated to engineering integrated data and technology solutions that help achieve the best possible outcomes for patients.

Azzur

Azzur Group provides the life science community with full lifecycle solutions for all their GxP needs. From Azzur Cleanrooms on Demandâ„¢ facilities, to labs, training centers, and consulting and advisory offices across the nation, Azzur helps organizations start, scale, and sustain their enterprises. With four decades of service to the industry, we`ve become a trusted partner to leading pharmaceutical, biotechnology, medical device, and healthcare companies, as well as their supply chain.

Tobira Therapeutics

Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.